SAGA Diagnostics and SensID collaborate on ultra-low allelic frequency control reagents for cancer mutations

15. July 2020Uncategorized

Rostock and Lund, 15 of July 2020 SensID GmbH, headquartered in Rostock, Germany, is a specialist for development and production of reference control materials for clinical genomics. SAGA Diagnostics AB, headquartered in Lund, Sweden, is a cancer genomics company focused on precision oncology and ultrasensitive liquid biopsy monitoring of cancer patients.  Today the two companies announce a … Read More

SensID product development in collaboration with Qiagen

21. April 2020Press releases

Rostock, 7th of April 2020  SensID GmbH, a Germany based provider of controls and reference materials for clinical genomics, today announces that it has developed a set of controls for the US FDA approved and CE-IVD marked therascreen PIK3CA RGQ PCR Kits from QIAGEN.  The CE-IVD therascreen PIK3CA RGQ PCR Kit was launched in Europe in February 2020 as an aid to the identification of activating PIK3CA mutations in samples of either FFPE tumour tissue or … Read More

SensID Inks Distribution Agreement with TATAA Biocenter for its MDx Reference Standards

14. May 2019Press releases

SensID GmbH, a leading specialist in the development and manufacturing of high quality reference standards for molecular diagnostics, and TATAA Biocenter AB, a pioneer within the industry and leading provider of high quality molecular analyses announced today the signing of a distribution agreement. SensID gives TATAA full access to its continuously growing product portfolio for … Read More